Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com
PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.
Featured Articles
Proadrenomedullin biomarker improves risk stratification and site of care decision in pneumonia patients
Initial severity assessment of emergency department patients with lower respiratory tract infections (LRTI) remains a clinical challenge. IHE spoke to Dr Philipp Schuetz, associate professor of internal medicine of the Medical University Clinic in Aarau, Switzerland, about his experience with ProADM, a new biomarker that has great potential to improve the current triage practice and thus site of care decisions.
Q. Is the risk assessment of patients who suffer from lower respiratory tract infection (LRTI) still a clinical need in hospitals?
Yes, LRTI is a serious condition associated with a significant rate of morbidity and long-term mortality. Additionally, LRTI has a major impact on the use of resources and healthcare expenditure. Although most patients are treated on an outpatient basis, the costs for hospitalized pneumonia patients can be 25 times higher [1]. Therefore, whether or not to hospitalize a patient is clinically of outmost importance and a very costly decision. Severity scores such as Pneumonia Severity Index (PSI) and/or the CURB65 were developed to aid the site of care decision and safely assess the risk of pneumonia patients. However, these scores have significant shortcomings which limit their applicability in routine care. First of all, they focus on mortality only, rather than on other complications, Secondly, they are static and do not include changes of the condition over time. Finally, they perform sub-optimally which should be improved to be able to make safe decisions for individual patients. Thus, there is still room to improve the current risk assessment tools and blood biomarkers like Proadrenomedullin (ProADM) which seems to show great potential in filling this gap [2-5].
Q. What is ProADM? How does it improve risk assessment in LRTI patients?
ProADM (mid-regional proAdrenomedullin) is a stable surrogate marker for Adrenomedullin (ADM). ADM belongs to the family of Calcitonin related peptides, similar to Procalcitonin (PCT). ADM is the most potent vasodilator and is activated in different stages of severe illness, such as sepsis and systemic infections. Unlike PCT, ADM is not specific to infections, but increases in different conditions that correlate with severity and adverse outcome across different medical diseases. Therefore, ProADM is not a diagnostic marker for sepsis, but has prognostic abilities. Importantly, proADM is also dynamic over time and the levels decrease when a patient improves; it also correlates with the risk of adverse events.
In several studies, ProADM showed a high correlation with the severity of LRTI; it was better than other commonly used parameters (WBC, PCT and CRP) and as powerful as PSI and CURB-65. Interestingly, when ProADM was used in addition to clinical risk scores, the accuracy of PSI and CURB-65 for risk prediction was improved for both short-term and long-term mortality.
Q. What is the benefit of adding ProADM to clinical risk assessment?
ProADM allows physicians to objectively estimate a patient
Private hospitals in China and India: medical equipment demand to soar
Depending on who is speaking, the rise of China and India is seen as an opportunity, a threat or a mix of both. Measured by purchasing power, the World Bank lists the two Asian giants as the world
Scientific literature review: MR
The number of peer-reviewed papers covering the field of magnetic resonance (MR) is huge, to such an extent that it is frequently difficult for healthcare professionals to keep up with the literature. As a special service to our readers, International Hospital presents a few key literature abstracts from the clinical and scientific literature chosen by our editorial board as being particularly worthy of attention.
Clinical MRI of acute ischemic stroke
Gilberto Gonz
Hospital goes fully digital Moving to wireless DRX-1 technology
International Hospital spoke to Professor Johan De Mey, the Head of the Department of Radiology at UZ Brussel hospital in Brussels. With nearly 800 beds, the hospital is one of the seven university hospitals in Belgium with around 200 000 patient contacts a year in radiology across a variety of disciplines. Professor De Mey talks about how upgrading their existing mobile equipment from phosphor plates to high quality DR technology has delivered higher productivity, excellent image quality and enhanced patient care.
Q. UZ Brussels finally achieved full digital status across the hospital. What are the advantages for the patients and the staff?
We first partnered with Carestream over a decade ago with the installation of PACS and with the introduction of Carestream DRX equipment. There are so many advantages. First of all, there is no image loss which is very important in emergency situations. What
Predictive models and severity measurements in the ICU
The fundamental role of severity measurements in the intensive care unit (ICU) is the comparative audit. Assessing the risk of each patient